Time-restricted eating in Huntington's disease: first clinical signals

Time-restricted eating in Huntington's disease presents an unusual problem. Unintentional weight loss is already a major concern in this neurodegenerative condition, so asking people to spend roughly 16 hours each day without calories could plausibly make matters worse. Yet in the first clinical pilot study of this approach, 20 participants maintained their weight over 12 weeks — while several disease-related measures moved in a favourable direction.

The intervention was not designed as calorie restriction. Adults with early-stage Huntington's disease were asked to consume their normal calories within a self-selected daily window of roughly six to eight hours, while also receiving standard dietary and activity advice.

This was an open-label, single-arm study: there was no untreated comparison group, and every participant knew what intervention they were following. Its first task was therefore practical rather than therapeutic. Could people with Huntington's disease follow such a schedule without worsening the weight loss that often accompanies the condition?

A fasting schedule in a disease where weight loss matters

Huntington's disease is an inherited neurodegenerative disorder that progressively affects movement, cognition and behaviour. As the disease advances, maintaining body weight can become increasingly difficult.

That makes meal timing a particularly delicate intervention. Animal studies have suggested that periods without caloric intake can influence circadian regulation, autophagy, metabolism and mitochondrial function. But any theoretical neuroprotective benefit would be of little value if the same schedule caused people with Huntington's disease to lose additional weight.

Over the 12-week intervention, that concern did not materialize. Participants followed the prescribed eating schedule on average more than five days per week, and most adapted during the first one to two weeks. Body weight and lean mass remained stable, and the regimen was generally well tolerated.

For a pilot trial, that feasibility result is important in its own right: a dietary schedule that could reasonably have aggravated a known problem in Huntington's disease was manageable without measurable loss of weight or lean tissue.

Neurofilament light fell by 13%

The exploratory biological findings were more surprising.

After 12 weeks, plasma neurofilament light declined by an average of 13%. Neurofilament light is a structural protein from nerve fibres that enters the circulation when neuroaxonal damage occurs. Its concentration tends to rise as Huntington's disease progresses, making it a useful biomarker of neurodegeneration.

Participants also improved by about 0.5 points on the composite Unified Huntington's Disease Rating Scale, or cUHDRS, which combines measures of motor function, cognition and functional capacity.

The researchers additionally measured mitochondrial bioenergetics in peripheral blood cells and observed favourable changes in several measures of cellular respiration. These results are consistent with the idea that fasting intervals can alter cellular energy metabolism. They do not, however, demonstrate improved mitochondrial function inside neurons: the measurements came from circulating blood cells.

The 13% neurofilament decrease also requires careful interpretation. Without a control group eating on its usual schedule, the study cannot separate an effect of meal timing from short-term biological variation, characteristics of this small sample or other behavioural changes during participation.

Clinical scores face a similar problem. Repeating cognitive tests can itself improve performance, and this exploratory study examined multiple outcomes without adjusting reported P values for multiple comparisons.

The trial answered the first question, not the final one

The study therefore does not establish that time-restricted eating slows Huntington's disease. Its strongest result is more foundational: people with early-stage disease were able to sustain the regimen for three months without losing body weight or lean mass.

That makes the simultaneous fall in neurofilament light worth testing under much stricter conditions rather than treating it as proof of benefit.

The next experiment has a straightforward logic. Give comparable groups the same nutritional support, but ask only one group to confine calories to a short daily window. If their biomarkers and clinical trajectories then separate, researchers will have a much stronger answer to a surprisingly simple question: in Huntington's disease, can when people eat matter independently of what they eat?